Sanofi (SNY) Cash from Financing Activities (2013 - 2026)

Sanofi has disclosed Cash from Financing Activities across 7 years of filings, most recently posting -$1.8 billion for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$1.8 billion, down 187.09% year-over-year; the trailing twelve-month figure through Mar 2026 was -$22.3 billion (down 234.57% YoY), and the FY2025 annual result was -$9.5 billion, down 54.22% from the prior year.
• Cash from Financing Activities came in at -$1.8 billion for Q1 2026 at Sanofi, up from -$9.6 billion in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $825.6 million in Q1 2024 to a low of -$9.6 billion in Q4 2025.
• The 3-year median for Cash from Financing Activities is -$3.1 billion (2026), against an average of -$3.6 billion.
• Peak annual rise in Cash from Financing Activities reached 55.13% in 2025, while the deepest fall reached 510.48% in 2025.
• Sanofi's Cash from Financing Activities stood at -$6.2 billion in 2024, then slumped by 55.13% to -$9.6 billion in 2025, then jumped by 81.29% to -$1.8 billion in 2026.
• The last three Cash from Financing Activities figures came in at -$1.8 billion (Q1 2026), -$9.6 billion (Q4 2025), and -$6.6 billion (Q3 2025), per Business Quant data.